F2 and COVID-19: Up to 60% of critically ill COVID-19 patients develop COVID-19–associated coagulopathy (CAC), manifested by increased D-dimer levels, unchanged or modestly decreased platelet count, decreased prothrombin time or partial thromboplastin time, and an increased risk of microvascular or macrovascular thrombosis (13–16).